Literature DB >> 19105984

CXCL10 and autoimmune diseases.

Eun Young Lee1, Zang-Hee Lee, Yeong Wook Song.   

Abstract

CXCL10 is a 10 kDa protein, which is categorized functionally as a Th1-chemokine. It binds to the receptor CXCR3 and regulates immune responses through the activation and recruitment of leukocytes, such as, T cells, eosinophils, and monocytes. Recent reports have shown that serum and/or tissue expressions of CXCL10 are increased in various autoimmune diseases like rheumatoid arthritis (RA), systemic lupus rythematosus (SLE), Sjogren syndrome (SS), systemic sclerosis (SSc), and idiopathic inflammatory myopathy (IIM). Moreover, CXCL10 and CXCR3 may have important roles in leukocyte homing to inflamed tissues and in the perpetuation of inflammation, and therefore, tissue damage. Our recent study shows that CXCL10 also has a pathogenic role in bone destruction via receptor activator of NF-kappaB ligand (RANKL) induction in inflamed synovial tissue of RA. In addition to its chemotactic effect, CXCL10 may have pleiotropic functions. Further research on the function of this chemokine and interactions between CXCL10 and other cytokines and chemokines may provide therapeutic targets in various autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19105984     DOI: 10.1016/j.autrev.2008.12.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  103 in total

1.  Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.

Authors:  Yin Liu; Yuval Ramot; Antonio Torrelo; Amy S Paller; Nuo Si; Sofia Babay; Peter W Kim; Afzal Sheikh; Chyi-Chia Richard Lee; Yongqing Chen; Angel Vera; Xue Zhang; Raphaela Goldbach-Mansky; Abraham Zlotogorski
Journal:  Arthritis Rheum       Date:  2012-03

2.  Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.

Authors:  Aniko Rentka; Jolan Harsfalvi; Gabriella Szucs; Zoltan Szekanecz; Peter Szodoray; Krisztina Koroskenyi; Adam Kemeny-Beke
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART.

Authors:  L A Ramirez; T A Arango; E Thompson; M Naji; P Tebas; J D Boyer
Journal:  J Leukoc Biol       Date:  2014-08-25       Impact factor: 4.962

4.  Identifying a role for Toll-like receptor 3 in the innate immune response to Chlamydia muridarum infection in murine oviduct epithelial cells.

Authors:  Wilbert A Derbigny; LaTasha R Shobe; Jasmine C Kamran; Katherine S Toomey; Susan Ofner
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

Review 5.  Body mass index and colon cancer screening: the road ahead.

Authors:  Kanwarpreet Tandon; Mohamad Imam; Bahaa Eldeen Senousy Ismail; Fernando Castro
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

6.  Reproductive immunology: current status and future directions (part I).

Authors:  Elena Peeva
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

7.  Nicotine stimulates expression of proteins implicated in peripheral and central sensitization.

Authors:  J L Hawkins; J E Denson; D R Miley; P L Durham
Journal:  Neuroscience       Date:  2015-01-28       Impact factor: 3.590

Review 8.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

9.  CXCL10 production by human monocytes in response to Leishmania braziliensis infection.

Authors:  Diego A Vargas-Inchaustegui; Alison E Hogg; Gianfranco Tulliano; Alejandro Llanos-Cuentas; Jorge Arevalo; Janice J Endsley; Lynn Soong
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

10.  The emerging role of CXCL10 in cancer (Review).

Authors:  Mingli Liu; Shanchun Guo; Jonathan K Stiles
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.